BioSpace News Archive

Ascletis Pharma Inc. announces that Dr. Zhengqing Li joins Ascletis as Chief Medical Officer and President of R&D Greater China, reporting to Jinzi J. Wu, PhD., Founder, Chairman and CEO of Ascletis.

Welltower Inc. announced that it has completed the previously announced conversion of all of its outstanding Series I Cumulative Convertible Perpetual Preferred Stock into the Company’s common stock pursuant to the terms of the Convertible Preferred Stock.

Inkspace Imaging Closes Its First Round Of Private Funding In 2019

Agreement enhances ability for basic enzyme production to increase Kemin capabilities to serve more customers globally in the feed, food and textiles markets

Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease

Vejthani Hospital in Bangkok announced the opening of a wound care center to offer comprehensive treatment for diabetic foot ulcers.

Karolinska Development’s portfolio company Aprea Therapeutics announces that funds managed by Janus Henderson Investors has joined its Series C financing as a new investor, raising the total amount of the financing from EUR 50 to EUR 55 million.

MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has reported that the U.S. Food and Drug Administration has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.

Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers

NOXXON Pharma N.V. announced that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices, to start a Phase 1/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.